Federal contract award
75N93023C00014
THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $3.6M |
| Current contract value | $3.6M |
| Potential contract value / ceiling | $3.6M |
| Start date | Jul 1, 2023 |
| Current end date | Jun 30, 2027 |
| Potential end date | Jun 30, 2027 |
| Latest award activity | Jul 28, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 9 of 9 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 28, 2026 | P00008 | $109.2K | THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE |
| Jul 16, 2026 | P00007 | $0 | EO 14398 |
| Apr 29, 2026 | P00006 | $0 | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI BILATERAL MODIFICATION TO DESCOPE WORK. |
| Jul 14, 2025 | P00005 | $499.9K | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI BILATERAL MODIFICATION TO DESCOPE WORK. |
| Mar 18, 2025 | P00004 | $0 | THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE |
| Jun 6, 2024 | P00003 | $1.5M | THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE |
| May 15, 2024 | P00002 | $0 | THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE |
| Aug 14, 2023 | P00001 | $0 | THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE |
| Jun 29, 2023 | 0 | $1.5M | THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-06-30 (248 days from calculation)
- +35 points
- 103 historical awards in this buyer and category group
- +15 points
- 9 recorded award transactions
- +10 points
- Latest award action: 2026-07-28
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.